Pathology in Practice talks to Beckman Coulter’s Ibti Rashid about recent acquisitions and the role of automation in microbiology, with particular focus on the Iris urine testing solution.
Iris has always had an outstanding reputation in automated urinalysis products, says Beckman Coulter’s senior marketing manager Ibti Rashid. Beckman Coulter’s focus on performance and increasing laboratory productivity made its acquisition of Iris a perfect fit. While globally it already offers world-leading solutions for automation, chemistry, immunoassay and haematology, Beckman Coulter saw that Iris would open the door to entry into the area of microbiology. It also adds Iris’s unique technology in cell imaging, which has the potential to enhance the capability of Beckman Coulter’s future haematology systems.
“The combination of Beckman Coulter’s investment power, with the service excellence that customers always receive from Iris, has already had a beneficial effect on the Beckman Coulter Iris urinalysis business,” explained Mrs Rashid.
With the increasing trend for pan-pathology tenders to include microbiology, Iris now forms a fundamental part of the Beckman Coulter offering in such proposals. The success of this solution is becoming more apparent, with Beckman Coulter Iris being included increasingly in competitor tenders as the preferred supplier.
Log in or register FREE to read the rest
This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text.
If you don't already have an account, please register with us completely free of charge.